Greatbatch, Inc. and Enpath Medical, Inc. Announce Expiration of HSR Waiting Period for Acquisition

  
    
  
  
    
      Greatbatch, Inc. (NYSE:GB) and Enpath Medical, Inc. (NASDAQ:NPTH) 
      announced today that the waiting period under the Hart-Scott-Rodino 
      Antitrust Improvements Act of 1976 (HSR) with respect to Greatbatch’s 
      acquisition of Enpath has expired.
    
    
      On May 8, 2007, Greatbatch commenced an all-cash tender offer for all of 
      the outstanding shares of Enpath common stock for $14.38 per Enpath 
      share. The tender offer is being made pursuant to the definitive merger 
      agreement unanimously approved by the Boards of Directors of both 
      companies and announced on April 30, 2007. The Enpath Board of Directors 
      has unanimously recommended that Enpath shareholders tender their shares 
      into the offer.
    
    
      The tender offer will expire at 12:00 midnight New York City time, on 
      Tuesday, June 5, 2007 (the end of the day on Tuesday), unless extended. 
      Following successful completion of the tender offer, holders of any 
      remaining outstanding shares of Enpath will be entitled to receive cash 
      of $14.38 per share of Enpath common stock upon closing of the 
      acquisition.
    
    
      As previously announced, the transaction is subject to customary closing 
      conditions, as well as the valid tender of a majority of the outstanding 
      shares of Enpath common stock, on a fully-diluted basis. The expiration 
      of the HSR waiting period has satisfied one of the closing conditions. 
      Greatbatch expects to close the transaction in late June.
    
    
      The complete terms and conditions of the tender offer are set forth in 
      the Offer to Purchase and certain additional information is set forth in 
      the Solicitation/Recommendation Statement of Enpath, copies of which are 
      available by contacting Georgeson, the Information Agent for the tender 
      offer, at 1-866-580-6912 toll free. The Dealer Manager for the tender 
      offer is Banc of America Securities LLC.
    
    
      About Greatbatch
    
    
      Greatbatch, Inc. is a leading developer and manufacturer of critical 
      components used in implantable medical devices and other technically 
      demanding applications.
    
    
      About Enpath Medical
    
    
      Enpath Medical, Inc., headquartered in Plymouth, Minnesota, is a leader 
      in the design, development, manufacture and marketing of percutaneous 
      delivery systems and stimulation leads technologies. Its proprietary 
      products include venous vessel introducers, articulating and fixed curve 
      delivery catheters, epicardial and endocardial stimulation leads, and 
      other products for use in pacemaker, defibrillator, catheter and 
      infusion port procedures as well as neuromodulation markets. Its 
      products, which are primarily finished goods, are sold worldwide through 
      partnering relationships with other medical device companies.
    
    
      Forward-Looking Statements
    
    
      This press release contains forward-looking statements regarding the 
      proposed transaction between Greatbatch and Enpath, including a 
      statement regarding the anticipated closing of the above described 
      acquisition. These statements are based on current expectations, 
      forecasts and assumptions. Actual results could differ materially from 
      those anticipated by these forward-looking statements as a result of a 
      number of factors, some of which may be beyond Greatbatch’s 
      or Enpath’s control. Among other things, these 
      factors include the risk that the acquisition will not be completed 
      because the tender offer did not proceed as anticipated or closing 
      conditions to the acquisition were not satisfied. For a further list and 
      description of risks and uncertainties associated with Greatbatch’s 
      and Enpath’s businesses, see their reports 
      filed with the Securities and Exchange Commission (SEC), including the “Risk 
      Factors” section in each company’s 
      most recent annual report on Form 10-K. The companies disclaim any 
      intention or obligation to update or revise any forward-looking 
      statements, whether as a result of new information, future events or 
      otherwise, except as required by law.
    
    
      Additional Information
    
    
      This communication is neither an offer to purchase nor a solicitation of 
      an offer to sell any securities. The offer to buy shares of Enpath 
      common stock is being made pursuant to a Tender Offer Statement filed by 
      Greatbatch and its subsidiaries with the SEC on Schedule TO on May 8, 
      2007. A Solicitation/Recommendation Statement with respect to the offer 
      was filed by Enpath with the SEC on Schedule 14D-9 on May 8, 2007. 
      Enpath shareholders are advised to read the Tender Offer Statement and 
      the related Solicitation/Recommendation Statement. These documents 
      contain important information that should be read carefully before any 
      decision is made with respect to the offer. These documents are 
      available to all shareholders of Enpath at no expense to them. These 
      documents are available at no charge on the SEC’s 
      web site at www.sec.gov. Shareholders 
      may also obtain copies of these documents without charge by requesting 
      them from Georgeson, the Information Agent, at 1-866-580-6912 toll free.